Endocrine Essentials Pro - St. Louis

St. Louis, MO US

The Endocrine Society brings top-quality clinical updates to your area with Endocrine Essentials Live. This regional series features two programs designed for both professional endocrinologists and for primary care physicians treating endocrine-related diseases.

To claim CME

  • This form is for the Endocrine Essentials Pro meeting in St. Louis, MO on September 27, 2014
  • To evaluate this meeting and claim CME, click "Take Course" to the right

Target Audience

The third year of this regional series is designed for clinical endocrinologists and endocrine fellows, providing a focused clinical endocrine update covering acromegaly, male reproduction, obesity, and bone.

Learning Objectives

Upon completion of this educational activity, learners will be able to:


  • Recognize clinical features of acromegaly and select appropriate diagnostic tests
  • Select appropriate treatment options for patients with acromegaly
  • Discuss the role of somatostatin analogs, dopamine agonists, and GH receptor antagonists in the management of acromegaly
  • Discuss the efficacy and safety of treatment options in acromegaly
  • Apply updated practice guidelines in a clinical setting

Hypogonadism/Male Infertility

  • Summarize the discussions of the validity of low testosterone
  • Perform appropriate evaluation of symptomatic men to determine if they are androgen deficient
  • Explain the rationale behind key accountability and quality improvement measures in the diagnosis and management of men with androgen deficiency

Osteoporosis and Metabolic Bone Disease

  • Describe the pathophysiology and differential diagnosis of hypoparathyroidism
  • Recognize skeletal and non-skeletal sequelae of hypoparathyroidism and risks in treatment
  • Understand the mechanism and utility of emerging therapies in the management of hypoparathyroidism
  • Summarize current clinical studies on the safety and efficacy of human parathyroid hormone treatment in hypoparathyroidism

New and Emerging Therapies in Osteoporosis

  • Recognize risk factors and select appropriate screening for osteoporosis and metabolic bone disease in high risk individuals
  • Select pharmacological strategies for treating osteoporosis and metabolic bone disease to reach optimal bone mineral density levels and minimize side effects
  • Summarize the mechanism of action of emerging drug classes used to treat osteoporosis and metabolic bone disease


  • Identify the clinical and behavioral barriers to achieving weight loss and preventing weight gain in overweight and obese patients
  • Explain the clinical benefits of losing 5% to 10% of excess body weight
  • Explore how newly-approved and emerging weight- loss drugs may be appropriately integrated into a weight-loss program
  • Discuss the clinical data on new pharmaceutical treatment options for obesity
  • Recognize the behavioral approaches to obesity management that are most impactful in practice
  • Define medically significant weight loss and its impact on glycemic parameters
  • Select appropriate medical therapy options for the co-management of diabetes and obesity

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Bone and Calciotropic Hormones
General Endocrinology
Men’s Health
Neuroendocrinology and Pituitary
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 5.00 AMA PRA Category 1 Credits
  • 5.00 CME Certificate of Participation
Course opens: 
Course expires: 
Sheraton St. Louis City Center
400 South 14th Street
St. Louis, MO 63103
United States

Daniel Bessesen, MD – University of Colorado

Bart Clarke, MD – Mayo Clinic (Rochester, MN)

Michael Irwig, MD – George Washington University

Andrea Utz, MD, PhD – Vanderbilt University


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

Daniel H. Bessesen, MD: DSMB Member, Enteromedics

Bart Clarke, MD: DSMB Member, Amgen; Investigator, NPS Pharmaceuticals
Andrea Utz, MD, PhD: Principal Investigator, Ipsen, Novartis

The following faculty reported no relevant financial relationships: Michael Irwig, MD

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 5.00 AMA PRA Category 1 Credits
  • 5.00 CME Certificate of Participation